Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle.
about
VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingImproved elongation factor-1 alpha-based vectors for stable high-level expression of heterologous proteins in Chinese hamster ovary cells.Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2siRNA silencing of calumenin enhances functional factor IX production.Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiencyEngineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk.Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfectionUse of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarinIndustrial production of clotting factors: Challenges of expression, and choice of host cells.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Approaches for recombinant human factor IX production in serum-free suspension cultures.Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line.Significant differences in integration sites of Moloney murine leukemia virus/Moloney murine sarcoma virus retroviral vector carrying recombinant coagulation factor IX in two human cell lines.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Functional Study of the Vitamin K Cycle Enzymes in Live Cells.Recombinant human butyrylcholinesterase as a new-age bioscavenger drug: development of the expression system.Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme.Stable and high-level production of recombinant Factor IX in human hepatic cell line.Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX.r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin.Coagulation Factor IX for Hemophilia B Therapy.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Accumulation of functional recombinant human coagulation factor IX in transgenic soybean seeds.Intermediate purification of CHO-derived recombinant human Factor IX using hydrophobic interaction membrane-based chromatography and its comparison to a sulfated resin.Human Cells as Platform to Produce Gamma-Carboxylated Proteins.A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.
P2860
Q26799185-1C808C71-3F77-4DE4-9F37-ADA1ED8C7FF8Q26823542-9A3748FC-50D4-4FAB-9693-0C00C92B4F8AQ27008360-3726C168-AAFD-456A-B283-D07CF2C68CC8Q35188321-84825989-9A53-45BD-8C56-A4CE0588C45AQ35221146-DB6A8D21-289E-4C39-A0DB-D33C739C0A19Q35848852-C6CE4C4B-80C4-4B1A-B0C0-8A13C2029EFEQ35849078-B9024DE6-FB8A-46EF-A243-C11B5111C5E1Q36099126-306091C5-3C8D-4996-95DE-8FD1A2263381Q36599219-58D9568C-D8CE-41EF-A6BA-010BB38612B1Q36914625-2F2A82F8-CB15-4166-A2E9-385A6D57C73BQ37196787-20794042-79DE-4095-9179-A20E8BC5B9A1Q38534584-86AD59FB-57DC-484A-B28D-89B67A168ADFQ38750444-7FBABD68-49EB-43A2-8F3C-C133936B5E73Q38819734-D18AEA5F-AE56-4344-BFA6-4831639EC138Q38860655-06A27818-DEAF-489F-BD1A-B6D14D1C24BFQ38913136-1225A897-2A38-443B-9970-629202EA1DCDQ38961083-3A3FDA29-E76C-4481-A96F-DF12CEE2F8DAQ39074534-B8C59CEF-DDC8-4F70-84DD-3D1EBF116066Q39171367-33DF37E4-54F9-4B6D-8266-3D7B9AC5717BQ39455669-D77024E6-DB8B-47C0-82FE-08BFC8E706C5Q39490991-E84FB599-D4C1-4AD7-8BE4-3FDF44F1EDBCQ40059443-3903F175-0B3E-4DCB-AB1E-7C077B29A95AQ40288458-975D1FAC-8F25-418F-8455-ABB7D2791F9CQ42009729-71E13081-C8C2-45BC-A4AB-358B2AFFC608Q42256024-6EF0ABA5-08A2-45F4-A652-6C16EC126B56Q42335970-80760F75-CDCC-4836-B4CB-40B81A51AEC4Q45932052-AE319B8C-461D-430F-8386-EF4CB24587D6Q47719455-FC7C7384-A306-439C-9624-A83E7E6DDFDBQ47786940-0685FA25-8198-4C2F-A8BC-9B77532FFBC6Q53689662-05F38C84-30E1-438C-80BB-FC70A0302B6F
P2860
Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Increased production of functi ...... enzyme of the vitamin K cycle.
@en
type
label
Increased production of functi ...... enzyme of the vitamin K cycle.
@en
prefLabel
Increased production of functi ...... enzyme of the vitamin K cycle.
@en
P2093
P2860
P356
P1476
Increased production of functi ...... enzyme of the vitamin K cycle.
@en
P2093
Nadeem Wajih
Reidar Wallin
Susan M Hutson
P2860
P304
31603-31607
P356
10.1074/JBC.M505373200
P407
P577
2005-07-19T00:00:00Z